Core Nursing Explanation
Key Concept Analysis: This question tests the critical safety step before administering any vaccine, specifically the
Pneumococcal polysaccharide vaccine (PPSV23). The core principle is
preventing harm by ensuring the patient is an appropriate candidate for the vaccine. For a patient with
Chronic Obstructive Pulmonary Disease (COPD), who is at high risk for pneumococcal pneumonia, vaccination is a key preventive measure. However, administering it incorrectly (e.g., repeating a dose too soon, giving it when contraindicated) can be ineffective or cause adverse reactions.
Answer Rationale:
Key Point! The most comprehensive and primary safety action is to
verify the client's vaccination history and contraindications. This single step encompasses several critical checks:
- Previous Doses: PPSV23 is typically a one-time vaccine for adults. Administering a second dose too soon (less than 5 years after the first) increases the risk of severe local reactions.
- Contraindications: This includes a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose or any component of the vaccine.
- Precautions: While not absolute contraindications, conditions like moderate or severe acute illness might warrant postponing vaccination.
This action is the foundation upon which all other assessments are built. Without confirming it's safe to give the vaccine, other actions like checking vital signs are premature.
Distractor Analysis:
- Watch out for confusion! Option 1 (Check immunosuppressive drugs): While important, this is a more specific check often prioritized for live attenuated vaccines (e.g., MMR, varicella). PPSV23 is an inactivated (polysaccharide) vaccine and is generally safe for immunocompromised individuals, though the immune response may be suboptimal. It is not the most important universal pre-vaccination step.
- Option 2 (Assess vital signs and respiratory status): This is a standard part of a general nursing assessment and is crucial for monitoring the patient's baseline, especially with COPD. However, it does not specifically address the unique safety requirements for vaccine administration. A patient with stable COPD can still receive the vaccine.
- Option 3 (Review allergy history and previous vaccine reactions): This is a critical component of verifying contraindications, making it a part of the correct answer (Option 4). However, by itself, it is incomplete. It misses other key elements like previous dose timing and other specific contraindications (e.g., age under 2 years for PPSV23). Option 4 is a more comprehensive action.
Related Concepts: Understanding the difference between vaccine types (live vs. inactivated) guides nursing priorities. The nursing process dictates that
assessment (verifying history/contraindications) must precede
implementation (administering the vaccine). Patient education about potential side effects (e.g., sore arm, low-grade fever) is also a key nursing responsibility after administration.